SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bellevue Global Life Science Investors LLC

(Last)

(First)

(Middle)

10900 NE 4TH STREET, SUITE 2300

(Street)

BELLEVUE

98004

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Bellevue Life Sciences Acquisition Corp. [ BLAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/14/2023		J⁽²⁾		20,000	D⁽²⁾	$0.00	1,705,000⁽¹⁾⁽²⁾	D
Common Stock	02/14/2023		J⁽³⁾		20,000	D⁽³⁾	$0.00	1,685,000⁽¹⁾⁽³⁾	D
Common Stock	02/14/2023		J⁽⁴⁾		20,000	D⁽⁴⁾	$0.00	1,665,000⁽¹⁾⁽⁴⁾	D
Common Stock	02/14/2023		J⁽⁵⁾		20,000	D⁽⁵⁾	$0.00	1,645,000⁽¹⁾⁽⁵⁾	D
Common Stock	02/14/2023		J⁽⁶⁾		20,000	D⁽⁶⁾	$0.00	1,625,000⁽¹⁾⁽⁶⁾	D
Common Stock	02/14/2023		J⁽⁷⁾		225,000	D⁽⁷⁾	$0.00	1,400,000⁽¹⁾⁽⁷⁾	D
Common Stock	02/14/2023		J⁽⁸⁾		30,000	D⁽⁸⁾	$0.00	1,370,000⁽¹⁾⁽⁸⁾	D
Common Stock	02/14/2023		A⁽⁹⁾		430,000	A⁽⁹⁾	$10	1,800,000⁽¹⁾⁽⁹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Private Placement Warrants	$11.5	02/14/2023		P		430,000		⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	430,000	$10	430,000	D
Warrant for Common Stock	$11.5	02/14/2023		J⁽¹¹⁾			20,000	⁽¹¹⁾	⁽¹¹⁾	Common Stock	20,000	$0.00	410,000	D
Warrant for Common Stock	$11.5	02/14/2023		J⁽¹²⁾			20,000	⁽¹²⁾	⁽¹²⁾	Common Stock	20,000	$0.00	390,000	D

Explanation of Responses:

1. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.

2. Represents the shares transferred by the Sponsor to Mr. Jin Whan Park for his board service.

3. Represents the shares transferred by the Sponsor to Mr. Steven Reed for his board service.

4. Represents the shares transferred by the Sponsor to Mr. In Chul Chung for his board service.

5. Represents the shares transferred by the Sponsor to Mr. Husun Euh for his board service.

6. Represents the shares transferred by the Sponsor to Mr. Rad Roberts for his board service.

7. Represents the shares that were forfeited as a result of the underwriters' not exercising their over-allotment option.

8. Represents the shares transferred by the Sponsor to the underwriters.

9. The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock.

10. The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $11.50 per share, subject to adjustments. Each warrant will become exercisable 30 days after the Issuer's Public Offering. Each warrant will expire five years after the completion of the Issuer's Public Offering, or earlier upon redemption or liquidation.

11. Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Dr. In Chul Chung for his service as Chairman of the Audit Committee.

12. Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Steven Reed for his service as Chairman of the Board of Directors.

Remarks:

	By: Bellevue Capital Management LLC, Its Manager /s/ Kuk Hyoun Hwang, Managing Member	02/16/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.